Pharmaceutical PV DIV - FSB
Ended Awarded
- Contract number
- SPE2DU26FEMMX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,988
Award facts
- Contract value 100% obligated
- $83,987.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $84K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on November 14, 2025, represents a firm fixed-price purchase under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, with an ultimate completion date of November 17, 2025. The award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a critical supplier within the Defense Department's pharmaceutical supply chain, authorized to distribute a comprehensive range of products including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support military healthcare facilities.
This delivery order derives from DMS Pharmaceutical Group's broader single-award Indefinite Delivery Contract under the PPV-G GEN V program, which was established on November 13, 2025, with a $500 million ceiling and extends through December 31, 2036. The IDC includes a 30-month base period with three 30-month option periods, positioning the contractor as one of multiple regional prime vendor suppliers within the DLA's $30.3 billion pharmaceutical acquisition strategy. The company's extensive product portfolio encompasses oncology treatments, immunosuppressants, emergency medications, specialty surgical products, vaccines, and routine pharmaceuticals, enabling the contractor to fulfill diverse and specialized pharmaceutical requirements for Department of Defense military medical operations globally.
Quick answers
Who was awarded contract SPE2DU26FEMMX?
SPE2DU26FEMMX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DU26FEMMX worth?
The government has obligated $83,988 on SPE2DU26FEMMX.
Is contract SPE2DU26FEMMX an order under another contract?
Yes. SPE2DU26FEMMX is a delivery order under SPE2DU25D9517, an indefinite delivery contract.
Was contract SPE2DU26FEMMX competed?
The extent of competition for SPE2DU26FEMMX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award